RX-af01
/ Sun Yat-sen University
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
January 23, 2024
Safety and Efficacy of RX-af01 Combined With PD-1 Antibody
(clinicaltrials.gov)
- P1/2 | N=60 | Recruiting | Sponsor: Sun Yat-sen University | N=14 ➔ 60 | Trial completion date: Sep 2023 ➔ Dec 2024 | Trial primary completion date: Sep 2023 ➔ Dec 2024
Enrollment change • Metastases • Trial completion date • Trial primary completion date • Esophageal Squamous Cell Carcinoma • Oncology • Solid Tumor • PD-L1
October 13, 2022
Safety and Efficacy of RX-af01 Combined With PD-1 Antibody
(clinicaltrials.gov)
- P1/2 | N=14 | Recruiting | Sponsor: Sun Yat-sen University
New P1/2 trial • Esophageal Squamous Cell Carcinoma • Inflammation • Oncology • Solid Tumor • CD8 • PD-L1
1 to 2
Of
2
Go to page
1